A Clinical Trial to Evaluate the Effects of a Supplement on Markers of Female Fertility

NCT07740187 | Completed

• 2 other identifiers: 20729legacy-20729
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

This study evaluates the effects of a daily dietary supplement (WeNatal For Her) on markers of female fertility, reproductive health, and sexual health over three menstrual cycles. Forty female participants who are currently trying to conceive will take three capsules of the supplement each morning with their first meal. The study is a single-arm, unblinded hybrid trial. Participants will complete questionnaires at Baseline and on Days 2-5 of Cycles 1, 2, and 3, and will attend a local Labcorp location for blood draws at Baseline and at Cycle 3. Primary outcomes include blood-based biomarkers of female fertility (e.g., AMH, FSH, Estradiol), while secondary outcomes capture self-reported perceptions of reproductive health, energy levels, mood, and overall well-being.

Conditions

Female Infertility; Reproductive Health; Fertility; Hormonal Imbalance; Ovarian Reserve

Outcome Measures

Primary Outcomes (9)

• Change in Anti-Müllerian Hormone (AMH)

  Blood test measurement of serum AMH level to assess ovarian reserve

  Baseline and Day 2-5 of Cycle 3

• Change in Follicle-Stimulating Hormone (FSH)

  Blood test measurement of serum FSH level

  Baseline and Day 2-5 of Cycle 3

• Change in Estradiol

  Blood test measurement of serum Estradiol level

  Baseline and Day 2-5 of Cycle 3

• Change in Progesterone

  Blood test measurement of serum Progesterone level

  Baseline and Day 2-5 of Cycle 3

• Change in Testosterone

  Blood test measurement of serum Testosterone level

  Baseline and Day 2-5 of Cycle 3

• Change in 25-hydroxy Vitamin D

  Blood test measurement of serum 25-hydroxy Vitamin D level

  Baseline and Day 2-5 of Cycle 3

• Change in Serum Iron

  Blood test measurement of serum iron level

  Baseline and Day 2-5 of Cycle 3

• Change in Thyroid Stimulating Hormone (TSH)

  Blood test measurement of serum TSH level

  Baseline and Day 2-5 of Cycle 3

• Change in High-Sensitivity C-Reactive Protein (hs-CRP)

  Blood test measurement of serum hs-CRP level

  Baseline and Day 2-5 of Cycle 3

Secondary Outcomes (5)

• Change in Self-Reported Reproductive Health

  Baseline, Day 2-5 of Cycle 1, Day 2-5 of Cycle 2, and Day 2-5 of Cycle 3

• Change in Self-Reported Energy Levels

  Baseline, Day 2-5 of Cycle 1, Day 2-5 of Cycle 2, and Day 2-5 of Cycle 3

• Change in Self-Reported Mood

  Baseline, Day 2-5 of Cycle 1, Day 2-5 of Cycle 2, and Day 2-5 of Cycle 3

• Change in Self-Reported Breast Tenderness

  Baseline, Day 2-5 of Cycle 1, Day 2-5 of Cycle 2, and Day 2-5 of Cycle 3

• Change in Self-Reported Overall Well-Being

  Baseline, Day 2-5 of Cycle 1, Day 2-5 of Cycle 2, and Day 2-5 of Cycle 3

Study Arms (1)

WeNatal For Her Supplement

EXPERIMENTAL

Dietary Supplement: WeNatal For Her Supplement

Interventions

WeNatal For Her Supplement DIETARY_SUPPLEMENT

All 40 participants take three capsules of the WeNatal For Her supplement daily in the morning with their first meal for three menstrual cycles.

WeNatal For Her Supplement

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Be female.
• Be aged 18-45.
• In the past three menstrual cycles, has experienced issues with all of the following: Low energy levels and fatigue
• Bloating
• Breast tenderness
• Irritability or mood swings.
• Currently trying to conceive.
• Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
• Not planning on introducing any products or any new forms of prescription medication or supplements that target female fertility for the study duration.
• Has a regular menstrual cycle between 21 and 35 days in length and is able to predict the dates of their upcoming periods.
• Resides in the United States.
• Not currently partaking in another research study and will not be partaking in any other research study for the next three menstrual cycles and at any point during this study's duration.
• Willing to avoid all other prenatal vitamins for the duration of this study.

You may not qualify if:

• Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
• Anyone with any allergies or sensitivities to any of the study product ingredients.
• Any women who are currently pregnant or breastfeeding.
• Anyone taking anticoagulant or "blood thinning" medication.
• Anyone taking bisphosphonates or other prescription medications for osteoporosis.
• Anyone taking chemotherapy medication.
• Anyone diagnosed with hemochromatosis or elevated iron levels.
• Anyone who drinks heavily (i.e. eight or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men).
• Anyone unwilling to follow the study protocol.
• Anyone with a history of substance abuse.
• Anyone who is currently a smoker or has been a smoker in the past three months.
• Anyone who has stopped using hormonal birth control less than six months prior to starting the study.
• Anyone previously diagnosed with premenstrual dysphoric disorder (PMDD), endometriosis, or any cancer of the reproductive system.
• Anyone who is peri- or post-menopausal.

Sponsors & Collaborators

• WeNatal: lead
• Citruslabs: collaborator

Study Sites (1)

Citruslabs

Las Vegas, Nevada, 89118, United States

Location

MeSH Terms

Conditions

Infertility, Female

Condition Hierarchy (Ancestors)

Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Infertility

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 28, 2026
• First Posted: July 31, 2026
• Study Start: April 15, 2025
• Primary Completion: February 12, 2026
• Study Completion: February 12, 2026
• Last Updated: July 31, 2026

Record last verified: 2026-07

Locations

US (1)